Cancer Therapy News and Research

RSS

Actinium's Chairman to discuss role of alpha-particle radiopharmaceuticals at SNMMI Annual Meeting

Actinium Pharmaceuticals, Inc. ("Actinium" or "the Company"), a biopharmaceutical company developing innovative targeted payload immunotherapeutics for the treatment of advanced cancers, today announced that Actinium's Clinical Advisory Board Chairman Joseph Jurcic, MD will participate in an upcoming panel discussion highlighting the role of Actinium's alpha-particle radiopharmaceuticals in the treatment of leukemia patients.

9 Jun 2014

Research roundup: Funding for safety-net hospitals; insurance competition

Safety-net hospitals rely on disproportionate-share hospital (DSH) payments to help cover uncompensated care costs and underpayments by Medicaid

9 Jun 2014

SAP collaborates with MolecularHealth and GATC to offer personalized cancer treatment

In the spirit of its mission to improve people's lives, SAP AG today announced that it intends to offer a personalized treatment option service, in collaboration with MolecularHealth and GATC Biotech, to qualified employees fighting cancer.

6 Jun 2014

MolecularHealth launches innovative oncology program for employers

MolecularHealth announced today the official launch of MolecularHealth COPE (Corporate Oncology Program for Employers), powered by its cancer treatment decision support offering, TreatmentMAP.

6 Jun 2014

Data from Caris Registry clinical outcomes presented at ASCO annual meeting

Caris Life Sciences and investigators from Inova Fairfax Hospital presented the first clinical outcomes data presentation from the Caris Registry™ at the 50th annual meeting of the American Society of Clinical Oncology (ASCO) in Chicago, Ill., this weekend.

5 Jun 2014

Immune Design begins treatment in LV305 Phase 1 clinical trial for cancer

Immune Design, a clinical-stage immunotherapy company focused on the development of novel immune-based therapies for cancer and other chronic conditions, today announced treatment of the first patient in a Phase 1 clinical trial of LV305, an immuno-oncology investigational agent from the company's DCVexTM lentiviral vector platform.

5 Jun 2014

Gamma and neutron imaging safe and effective in simulations

Gamma and neutron imaging offer possible improvements over existing techniques such as X-ray or CT, but their safety is not yet fully understood.

5 Jun 2014

Bariatric surgery not only helps reduce weight, but lowers cancer risk among obese people

Weight loss surgery might have more value than simply helping morbidly obese people to shed unhealthy extra pounds.

5 Jun 2014

Synthetic peptide carrier delivers drugs through blood-brain barrier for cancer treatment

Researchers at Mayo Clinic have demonstrated in a mouse model that their recently developed synthetic peptide carrier is a potential delivery vehicle for brain cancer chemotherapy drugs and other neurological medications. The findings appear in PLOS ONE.

4 Jun 2014

AMS agrees to sell Gamma Knife and radiation therapy services business in Turkey to Euromedic

AMERICAN SHARED HOSPITAL SERVICES, a leading provider of turnkey technology solutions for advanced radiosurgical and radiation therapy services, announced today that it has entered into an agreement to sell its Gamma Knife and radiation therapy services business in Turkey to Euromedic Cancer Treatment Centers BV.

4 Jun 2014

Phone-based palliative care support program helps alleviate caregiver depression, burden

The earlier a specific phone-based, palliative care support program can be introduced to caregivers, the better they will be able to cope with the caregiving experience, according to research conducted by University of Alabama at Birmingham School of Nursing investigators.

4 Jun 2014

New technology can non-invasively image human lymphatic system

The human lymphatic system is an important but poorly understood circulatory system consisting of tiny vessels spread throughout the body.

4 Jun 2014

Nonadherence triples relapse risk in African American and Asian children in remission from ALL

An estimated 25 percent of children in remission from acute lymphocytic leukemia (ALL) are missing too many doses of an essential maintenance medication that minimizes their risk of relapse, according to a study published online today in Blood, the Journal of the American Society of Hematology.

3 Jun 2014

Enzalutamide drug proves effective in stemming progression of prostate cancer

A drug used to treat men with late-stage prostate cancer proved effective in stemming progression of the disease in research participants who had not yet received chemotherapy and extended their survival, according to results from a multi-national Phase III clinical trial led by the Knight Cancer Institute at Oregon Health & Science University.

3 Jun 2014

Ovarian cancer patients with molecular subtypes benefit from bevacizumab

Molecular sequencing could identify ovarian cancer patients who are most likely to benefit from treatment with bevacizumab (Avastin), a Mayo Clinic-led study has found.

2 Jun 2014

Ezyme used as target for antidepressants may also provide way to cure prostate cancer

An international team of scientists including researchers at the Cedars-Sinai Samuel Oschin Comprehensive Cancer Institute and the University of Southern California found that an enzyme commonly used as a target for antidepressants may also promote prostate cancer growth.

2 Jun 2014

Memorial Sloan Kettering Cancer Center, Quest Diagnostics partner for cancer tests

Memorial Sloan Kettering Cancer Center, the world's oldest and largest private cancer center, and Quest Diagnostics, the world's leading provider of diagnostic information services, today announced a joint collaboration that will utilize MSK's clinical and research insights into gene mutations associated with solid tumors.

From Quest Diagnostics 2 Jun 2014

Investigational drug for advanced bladder cancer shows promise for treatment of certain tumor types

A multi-center phase I study using an investigational drug for advanced bladder cancer patients who did not respond to other treatments has shown promising results in patients with certain tumor types, researchers report.

31 May 2014

HCV reactivation may not worsen survival outcomes for lymphoma patients with HIV

More than a quarter of HIV+ patients are also infected with the Hepatitis C virus (HCV), which may complicate treatment and care decisions after a cancer diagnosis. The specifics of those complications haven't been well-researched in the past. Results from a new Fox Chase Cancer Center study on this patient population may start filling in that gap.

31 May 2014

ASCO Expert Panel develops treatment guidelines for cancer-related fatigue

Fatigue is a debilitating problem for cancer patients undergoing treatment; however, it also poses a huge detriment after treatment and can significantly affect quality of life.

31 May 2014

Cancer Therapy News and Research

Actinium's Chairman to discuss role of alpha-particle radiopharmaceuticals at SNMMI Annual Meeting

Research roundup: Funding for safety-net hospitals; insurance competition

SAP collaborates with MolecularHealth and GATC to offer personalized cancer treatment

MolecularHealth launches innovative oncology program for employers

Data from Caris Registry clinical outcomes presented at ASCO annual meeting

Immune Design begins treatment in LV305 Phase 1 clinical trial for cancer

Gamma and neutron imaging safe and effective in simulations

Bariatric surgery not only helps reduce weight, but lowers cancer risk among obese people

Synthetic peptide carrier delivers drugs through blood-brain barrier for cancer treatment

AMS agrees to sell Gamma Knife and radiation therapy services business in Turkey to Euromedic

Phone-based palliative care support program helps alleviate caregiver depression, burden

New technology can non-invasively image human lymphatic system

Nonadherence triples relapse risk in African American and Asian children in remission from ALL

Enzalutamide drug proves effective in stemming progression of prostate cancer

Ovarian cancer patients with molecular subtypes benefit from bevacizumab

Ezyme used as target for antidepressants may also provide way to cure prostate cancer

Memorial Sloan Kettering Cancer Center, Quest Diagnostics partner for cancer tests

Investigational drug for advanced bladder cancer shows promise for treatment of certain tumor types

HCV reactivation may not worsen survival outcomes for lymphoma patients with HIV

ASCO Expert Panel develops treatment guidelines for cancer-related fatigue

Your guide to microplate readers for cancer research eBook

Advancing Intracellular Delivery with LumiPore®

How ELRIG Is Helping Mid-Career Scientists Navigate Leadership, Career Change and Redundancy

The role of UV-Vis in biopharma QC

Latest News